Home
→
Recerca
→
Articles, congressos, llibres
→
Articles
→
Browsing Articles by Author

Browsing Articles by Author "Vall d'Hebron Institut d'Oncologia"

Now showing items 1-9 of 9

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

Tabernero, Josep; Hozak, R.R.; Yoshino, Takayuki; Cohn, A.L.; Obermannova, R.; Bodoky, G.; Garcia Carbonero, R.; Ciuleanu, T.E.; Portnoy, D.C.; Prausova, J.; Van Cutsem, Eric (Elsevier, 2018)

Background: The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan ...
Binimetinib Encorafenib and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Van Cutsem, Eric; Huijberts, Sanne; Grothey, Axel; Yaeger, Rona; Cuyle, Pieter-Jan; Elez, Elena; Fakih, Marwan; Montagut, Clara; Peeters, Marc; Yoshino, Takayuki; Kopetz, Scott; Tabernero, Josep (Lippincott Williams & Wilkins, 2019)

To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, ...
Current developments in gastric cancer: from molecular profiling to treatment strategy

Alsina, Maria; Arrazubi, Virginia; Diez, Marc; Tabernero, Josep (SpringerNature, 2023)

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced ...
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

Montagut, Clara; Argilés, Guillem; Ciardiello, Fortunato; Poulsen, Thomas T.; Dienstmann, Rodrigo; Kragh, Michael; Kopetz, Scott; Lindsted, Trine; Ding, Cliff; Vidal, Joana; Tabernero, Josep (American Medical Association, 2018)

IMPORTANCE Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is frequently due to RAS and EGFR extracellular domain (ECD) mutations in metastatic colorectal cancer (mCRC). Some anti-EGFR-refractory ...
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

Kopetz, Scott; Grothey, Axel; Yaeger, Rona; Van Cutsem, Eric; Desai, Jayesh; Yishino, Takayuki; Wasan, Harpreet; Ciardiello, Fortunato; Loupakis, Fotio; Tabernero, Josep (Massachusetts Medical Society, 2019)

Colorectal cancers with BRAF mutations have an aggressive natural history and are often resistant to therapy. A treatment regimen that combined BRAF inhibition, MET inhibition, and blocking of EGFR signaling resulted in a ...
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

Grothey, Axel; Fakih, Marwan; Tabernero, Josep (Elsevier, 2021)

Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the United States and worldwide, despite recent improvements in cancer management. CRC, like many malignancies, is a heterogeneous disease, ...
Multicenter Phase I Study of Erdafitinib (JNJ-42756493) Oral Pan-Fibroblast Growth Factor Receptor Inhibitor in Patients with Advanced or Refractory Solid Tumors

Bahleda, Rastislav; Italiano, Antoine; Hierro, Cinta; Mita, Alain; Cervantes, Andrés; Chan, Nancy; Awad, Mark; Moreno, Víctor; Tabernero, Josep (American Association Cancer Research, 2019)

Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and Methods: Patients age >= 18 years with advanced solid tumors for which standard antineoplastic ...
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Tabernero, Josep; Hoff, Paulo M.; Shen, Lin; Ohtsu, Atsushi; Shah, Manish A.; Cheng, Karen; Song, Chunyan; Wu, Haiyan; Eng-Wong, Jennifer; Kim, Katherine; Kang, Yoon-Koo (Elsevier, 2018)

Background: Adding pertuzumab to trastuzumab and chemotherapy improves survival in HER2-positive early breast cancer and metastatic breast cancer. We assessed the efficacy and safety of pertuzumab versus placebo in combination ...
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

Hill, Andrew G.; Findlay, Michael P.; Burge, Matthew E.; Jackson, Christopher; Garcia Alfonso, Pilar; Samuel, Leslie; Ganju, Vinod; Karthaus, Meinolf; Amatu, Alessio; Tabernero, Josep (American Association Cancer Research, 2018)

Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI ...

Now showing items 1-9 of 9

Search RIUVic

Browse

All of DSpace
This Collection
- By Issue Date
- Authors
- Titles
- Subjects

Browsing Articles by Author "Vall d'Hebron Institut d'Oncologia"

Browsing Articles by Author "Vall d'Hebron Institut d'Oncologia"

Search RIUVic

Browse

All of DSpace

This Collection